Search alternatives:
significantly increased » significant increase (Expand Search)
increased decrease » increased release (Expand Search), increased crash (Expand Search)
significant bins » significant bias (Expand Search), significant bit (Expand Search), significant hits (Expand Search)
significant non » significant gap (Expand Search), significant amount (Expand Search)
significantly increased » significant increase (Expand Search)
increased decrease » increased release (Expand Search), increased crash (Expand Search)
significant bins » significant bias (Expand Search), significant bit (Expand Search), significant hits (Expand Search)
significant non » significant gap (Expand Search), significant amount (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
Table 1_Denosumab in patients with osteogenesis imperfecta and a historical control study with alendronate.docx
Published 2025“…</p>Results<p>Pediatric denosumab recipients exhibited significant LS-BMD (+30.3%, P<0.001) and FN-BMD gains (+38.7%, P=0.001) versus baseline, whereas adults showed non-significant increases (LS: +2.6%, P=0.100; FN: +4.4%, P=0.051). …”
-
15
Image 1_Denosumab in patients with osteogenesis imperfecta and a historical control study with alendronate.tif
Published 2025“…</p>Results<p>Pediatric denosumab recipients exhibited significant LS-BMD (+30.3%, P<0.001) and FN-BMD gains (+38.7%, P=0.001) versus baseline, whereas adults showed non-significant increases (LS: +2.6%, P=0.100; FN: +4.4%, P=0.051). …”
-
16
Image 2_Denosumab in patients with osteogenesis imperfecta and a historical control study with alendronate.tif
Published 2025“…</p>Results<p>Pediatric denosumab recipients exhibited significant LS-BMD (+30.3%, P<0.001) and FN-BMD gains (+38.7%, P=0.001) versus baseline, whereas adults showed non-significant increases (LS: +2.6%, P=0.100; FN: +4.4%, P=0.051). …”
-
17
-
18
-
19
-
20